Human Papillomavirus1 Type 6 L1 protein / Human Papillomavirus1 Type 11 L1 protein / Human Papillomavirus1 Type 16 L1 protein / Human Papillomavirus1 Type 18 L1 protein
Key facts
| Invented name |
Silgard
|
| Active substance |
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/111/2009
|
| PIP number |
Human Papillomavirus1 Type 6 L1 protein / Human Papillomavirus1 Type 11 L1 protein / Human Papillomavirus1 Type 16 L1 protein / Human Papillomavirus1 Type 18 L1 protein
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Infection by Human Papillomavirus
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Merck Sharp & Dohme (Europe) Inc.
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|